James H Essell MD

Oncology•Blue Ash, OH

Oncology Hematology Care, Inc.

Join to View Full Profile

4725 E Galbraith RdSte 320Blue Ash, OH 45236
Phone+1 513-751-2273
Fax+1 513-751-1840

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
University of Cincinnati College of MedicineClass of 1985

Certifications & Licensure

OH State Medical License 1981 - 2027
KY State Medical License 1997 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris
Blood Advances. 2024-12-10
11 citations
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich
Leukemia. 2024-01-01
99 citations
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...
Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
The Lancet. Oncology. 2022-08-01

Abstracts/Posters

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)
James Essell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Canopy Launches Platform-Wide Support for Bispecific AntibodiesSeptember 25th, 2024
OHC and Jewish Hospital 1st in Region to Offer Revolutionary Cancer Treatment for Multiple MyelomaAugust 13th, 2021

Professional Memberships

American Society of Clinical Oncology - ASCO
Member